Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.

Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
Clin Lymphoma Myeloma Leuk. 2019 Jul 03;:
Authors: Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ
Abstract
The treatment of adult acute lymphoblastic leukemia (ALL) has largely followed the successful pediatric model that uses multi-agent chemotherapy regimens. Although cytotoxic chemotherapy can induce complete remissions, elderly patients are frequently unable to tolerate its intensity owing to toxicities and comorbidities. Elderly patients particularly often relapse, leading to a 5-year overall survival (OS) of only 20%. In an effort to improve outcomes while minimizing toxicities, novel targeted therapies have been developed: monoclonal antibodies against CD19, CD20, and CD22; tyrosine kinase inhibitors; chimeric antigen receptor T-cell therapies; and BH3 mimetics. Here, we discuss advancements in the treatment of ALL and their places in the armamentarium for adult patients.
PMID: 31307896 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - July 2, 2019 Category: Cancer & Oncology Authors: Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research